RUNX1 / AML1 Blocking Peptide

General Information

Product

RUNX1 / AML1 Peptide

Description

Antigenic Blocking Peptide RUNX1 Protein

Verified Applications

Immunodepletion, Immunocompetition

Peptide Description

Synthetic Peptide

Accession #

GenBank: AAI36381.1

Physical Properties

Quantity

250 µg

Volume

100 µl

Form

Antigenic Blocking Peptide

Storage

-20⁰C for long term storage

Application Protocol

Competition/Depletion assay

Refer to competition assay protocol

Protein

Uniprot #

Q01196

Overview

CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis.

Molecular Function

ATP binding, DNA binding, calcium ion binding

Subcellular Location

Nucleus

Expression

Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.

Structure

Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize.

Alternative Nomenclature

Acute myeloid leukemia 1 protein antibody

alpha subunit core binding factor antibody

AML1 EVI 1 fusion protein antibody

Aml1 oncogene antibody

AMLCR 1 antibody

CBF alpha 2 antibody

Core binding factor runt domain alpha subunit 2 antibody

Core-binding factor subunit alpha-2 antibody

EVI1 antibody

HGNC antibody

Oncogene AML 1 antibody

PEBP2 alpha B antibody

Polyomavirus enhancer binding protein 2 alpha B subunit antibody

Run1 antibody

Runt-related transcription factor 1 antibody

SL3/AKV core binding factor alpha B subunit antibody